View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 17, 2020

Tonix to focus on precision medicine approaches for Covid-19

Tonix Pharmaceuticals has signed a research collaboration and option agreement with Columbia University to explore precision medicine approaches for vaccines and therapeutics against Covid-19.

Tonix Pharmaceuticals has signed a research collaboration and option agreement with Columbia University to explore precision medicine approaches for vaccines and therapeutics against Covid-19.

The partners will study the immune responses to Covid-19 in healthy volunteers who recovered from the disease or were asymptomatic. The focus will be on T-cell and antibody responses at the cellular level.

The research should help in better understanding of the detailed immune responses to the disease. Tonix added that the study will provide insights on targeting vaccines and therapeutics to suitable individuals for precision medicine.

Columbia University researchers Dr Ilya Trakht and Dr Sergei Rudchenko will lead the project.

Trakht’s team will investigate T-cell and antibody responses using different techniques, including at the cellular level via stimulation of T-cells in-vitro with SARS-CoV-2 antigens and the production of fully human monoclonal antibodies against the virus.

The aim of the project is to enable the isolation and characterisation of therapeutic, fully human monoclonal antibodies to the virus.

Meanwhile, Rudchenko’s project will work to generate DNA aptamer-based anti-idiotypes to some of the monoclonal antibodies identified by Trakht.

These type of aptamers could help in identifying biomarkers for protective CoV-2 immunity and enable precision medicine vaccines to protect against the disease.

Tonix Pharmaceuticals president and CEO Seth Lederman said: “We expect that more than one Covid-19 vaccine will ultimately be approved by the Food and Drug Administration (FDA) and a challenge for future research will be to determine which vaccine is appropriate for each individual.

“Data from this collaboration will provide a roadmap and tools to potentially guide these recommendations. It is also possible that new Covid-19 vaccines can be designed, which will be tailored to individuals by precision medicine.”

Last month, Tonix expanded its ongoing partnership with non-profit Southern Research to study T-cell immune responses to SARS-CoV-2.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU